Omkar Pharmachem Ltd (532167)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Omkar Pharmachem's revenue was ₹0.1 Cr (-35.7% year on year, +0.0% on the previous quarter), and net profit ₹-0.0 Cr (against a profit a year earlier); the operating margin was -10.7%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.1 | -35.7% | +0.0% |
| Operating profit | ₹-0.0 | to loss | to loss |
| Net profit | ₹-0.0 | to loss | to loss |
| EPS (₹) | -0.01 | to loss | to loss |
| Operating margin | -10.7% | — | — |
📢 Recent Corporate Announcements
Omkar Pharmachem announced that its Board of Directors approved the convening of the 31st Annual General Meeting (AGM) on September 30, 2026, in Ahmedabad. The Board approved the Directors' Report along with annexures for the financial year ended March 31, 2026, as well as proposals for material related-party transactions. In addition, M/s Maulik Bhavsar & Associates was appointed as the scrutinizer to oversee the AGM voting process.
- 31st AGM scheduled for Wednesday, September 30, 2026, at 10:30 AM in Ahmedabad
- Approved Directors' Report and annexures for FY ended March 31, 2026
- Approved material related-party transactions for shareholder approval
- Appointed M/s Maulik Bhavsar & Associates (Membership No: 11139) as voting scrutinizer
Omkar Pharmachem reported a net loss of Rs 1.00 Lakh for the quarter ended June 30, 2026, swinging from a profit of Rs 2.66 Lakhs in the same period last year. The company continues to report zero revenue from core operations (Net Sales), relying entirely on 'Other Operating Income' which fell 33.3% YoY to Rs 9.00 Lakhs. Total expenses of Rs 10.00 Lakhs, primarily driven by employee benefits (Rs 5.14 Lakhs), exceeded total income. With a negligible promoter holding of 0.03% and stagnant business activity, the company remains a micro-cap entity with weak fundamentals.
- Net Loss of Rs 1.00 Lakh for Q1 FY27 compared to a profit of Rs 2.66 Lakhs in Q1 FY26
- Zero revenue from core operations (Net Sales) reported for the quarter
- Other Operating Income declined by 33.3% YoY to Rs 9.00 Lakhs from Rs 13.50 Lakhs
- Total expenses stood at Rs 10.00 Lakhs, slightly up from Rs 9.92 Lakhs in the previous year's quarter
- Promoter holding remains extremely low at 0.03% as per latest available context
Omkar Pharmachem reported a net loss of Rs 1.00 Lakh for the quarter ended June 30, 2026, compared to a profit of Rs 2.66 Lakhs in the same period last year. The company recorded zero revenue from operations, with its total income of Rs 9.00 Lakhs derived entirely from other operating sources. Total expenses of Rs 10.00 Lakhs marginally exceeded income, leading to the loss. Given the company's small market cap of Rs 16 Cr and negligible business activity, the financial performance remains stagnant.
- Net loss of Rs 1.00 Lakh in Q1 FY27 vs a profit of Rs 2.66 Lakhs in Q1 FY26
- Revenue from operations remained at Rs 0.00 for the quarter
- Other operating income declined by 33.3% to Rs 9.00 Lakhs from Rs 13.50 Lakhs YoY
- Total expenses stood at Rs 10.00 Lakhs against total income of Rs 9.00 Lakhs
- Earnings Per Share (EPS) turned negative to -0.0099 from 0.0264 YoY
Omkar Pharmachem Ltd has scheduled a board meeting for August 13, 2026, to review and approve its unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap entity with a market capitalization of just ₹17 Cr and a very small revenue base, reporting only ₹0.47 Cr in total revenue for FY26. The trading window for designated persons will remain closed until August 15, 2026. Investors should note the company's negligible promoter holding of 0.03% and declining annual revenue trend.
- Board meeting scheduled for August 13, 2026, at 03:30 P.M. to approve Q1 results.
- Trading window for designated persons remains closed until August 15, 2026.
- Company reported a marginal net profit of ₹0.02 Cr in the most recent quarter (March 2026).
- Annual revenue for FY26 stood at ₹0.47 Cr, a decline from ₹0.54 Cr in FY25.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
